BR112014000774A2 - compostos imidazóis substituídos por 2-piridilam como inibidores de alk5 e/ou alk4, seus usos e composições - Google Patents
compostos imidazóis substituídos por 2-piridilam como inibidores de alk5 e/ou alk4, seus usos e composiçõesInfo
- Publication number
- BR112014000774A2 BR112014000774A2 BR112014000774A BR112014000774A BR112014000774A2 BR 112014000774 A2 BR112014000774 A2 BR 112014000774A2 BR 112014000774 A BR112014000774 A BR 112014000774A BR 112014000774 A BR112014000774 A BR 112014000774A BR 112014000774 A2 BR112014000774 A2 BR 112014000774A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridilam
- imidazoal
- alk4
- alk5
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507305P | 2011-07-13 | 2011-07-13 | |
| US61/507,305 | 2011-07-13 | ||
| PCT/KR2012/005617 WO2013009140A2 (en) | 2011-07-13 | 2012-07-13 | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014000774A2 true BR112014000774A2 (pt) | 2016-08-23 |
| BR112014000774A8 BR112014000774A8 (pt) | 2017-10-10 |
| BR112014000774B1 BR112014000774B1 (pt) | 2022-03-29 |
Family
ID=47506748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014000774-8A BR112014000774B1 (pt) | 2011-07-13 | 2012-07-13 | Compostos imidazóis substituídos por 2-piridila como inibidores de alk5 e/ou alk4, composição farmacêutica compreendendo-os e uso terapêutico dos mesmos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10155763B2 (pt) |
| EP (1) | EP2731949B1 (pt) |
| JP (1) | JP6094975B2 (pt) |
| KR (1) | KR101938368B1 (pt) |
| CN (1) | CN103764655B (pt) |
| AU (1) | AU2012281281B2 (pt) |
| BR (1) | BR112014000774B1 (pt) |
| CA (1) | CA2841252C (pt) |
| DK (1) | DK2731949T3 (pt) |
| ES (1) | ES2671581T3 (pt) |
| MX (1) | MX369576B (pt) |
| NO (1) | NO2861601T3 (pt) |
| PL (1) | PL2731949T3 (pt) |
| PT (1) | PT2731949T (pt) |
| RU (1) | RU2612958C2 (pt) |
| TR (1) | TR201808033T4 (pt) |
| WO (1) | WO2013009140A2 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10233170B2 (en) * | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| EP3221318B1 (en) | 2014-11-21 | 2021-08-25 | Rigel Pharmaceuticals, Inc. | Fused imidazole derivatives as tgf-beta inhibitors |
| US10071079B2 (en) * | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| WO2018019106A1 (zh) * | 2016-07-29 | 2018-02-01 | 上海璎黎药业有限公司 | 含氮芳香杂环化合物、其制备方法、药物组合物和应用 |
| JP2019534266A (ja) | 2016-10-14 | 2019-11-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用 |
| JP2020500177A (ja) | 2016-11-14 | 2020-01-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ３，４−ビピリジルピラゾール誘導体、およびその製造方法およびその医療応用 |
| WO2018171611A1 (zh) * | 2017-03-22 | 2018-09-27 | 江苏恒瑞医药股份有限公司 | 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用 |
| JP2020512400A (ja) | 2017-03-23 | 2020-04-23 | クラヴィウス ファーマシューティカルズ，エルエルシー | ＴＧＦβの阻害のための三置換イミダゾールおよび治療方法 |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
| WO2020041562A1 (en) * | 2018-08-22 | 2020-02-27 | Clavius Pharmaceuticals, Llc | Substituted imidazoles for the inhibition of tgf-beta and methods of treatment |
| EP3894401A2 (en) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D IP, LLC | Naphthyridine and quinoline derivatives useful as alk5 inhibitors |
| KR20210113314A (ko) * | 2019-01-10 | 2021-09-15 | 스미토모 다이니폰 파마 온콜로지, 인크. | 골수이형성 증후군을 치료하기 위한 alk5 억제제 |
| CN110563735B (zh) * | 2019-09-27 | 2022-03-29 | 江苏好收成韦恩农化股份有限公司 | 制备双氟磺草胺的方法 |
| CN114728941A (zh) | 2019-11-22 | 2022-07-08 | 施万生物制药研发Ip有限责任公司 | 作为alk5抑制剂的经取代的1,5-萘啶或喹啉 |
| CN114787145B (zh) * | 2019-11-28 | 2024-03-26 | 阿戈麦布西班牙股份有限公司 | 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物 |
| WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| BR112023000588A8 (pt) | 2020-07-15 | 2023-05-09 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
| EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| BR112023000592A2 (pt) | 2020-07-15 | 2023-01-31 | Chiesi Farm Spa | Derivados de pirido oxazina amino como inibidores de alk5 |
| EP4267584A1 (en) | 2020-12-23 | 2023-11-01 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| CN112759592A (zh) * | 2021-02-01 | 2021-05-07 | 无锡鸣鹭医药科技有限公司 | 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法 |
| CN117999077A (zh) | 2021-07-28 | 2024-05-07 | 株式会社蒂奥姆生物 | 用于预防或治疗肿瘤的药物组合物及其用途 |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| WO2023247592A1 (en) | 2022-06-22 | 2023-12-28 | Chiesi Farmaceutici S.P.A. | 5-(4-fluorophenyl)-2,3-dihydro-1h-imidazo[1,2-a]imidazole derivatives as alk inhibitors for the treatment of fibrosis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4175127A (en) * | 1978-09-27 | 1979-11-20 | Smithkline Corporation | Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles |
| US4719218A (en) * | 1985-12-12 | 1988-01-12 | Smithkline Beckman Corporation | Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor |
| CN86108538A (zh) * | 1985-12-12 | 1987-07-29 | 史密丝克莱恩贝克曼公司 | 5-脂肪氧合酶途径的抑制 |
| ZW24186A1 (en) * | 1985-12-12 | 1987-07-08 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
| CA2058952A1 (en) * | 1989-06-13 | 1990-12-14 | Nabil Hanna | Monokine activity interference |
| JPH04273877A (ja) * | 1991-02-28 | 1992-09-30 | Sumitomo Pharmaceut Co Ltd | 新規なイミダゾール誘導体 |
| EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
| US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2004024074A2 (en) * | 2002-09-13 | 2004-03-25 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| US7872020B2 (en) * | 2005-07-22 | 2011-01-18 | Eli Lilly And Company | TGF-β inhibitors |
-
2012
- 2012-07-13 WO PCT/KR2012/005617 patent/WO2013009140A2/en active Application Filing
- 2012-07-13 PT PT128118650T patent/PT2731949T/pt unknown
- 2012-07-13 KR KR1020147003555A patent/KR101938368B1/ko active IP Right Grant
- 2012-07-13 US US13/548,785 patent/US10155763B2/en active Active
- 2012-07-13 EP EP12811865.0A patent/EP2731949B1/en active Active
- 2012-07-13 CA CA2841252A patent/CA2841252C/en active Active
- 2012-07-13 PL PL12811865T patent/PL2731949T3/pl unknown
- 2012-07-13 TR TR2018/08033T patent/TR201808033T4/tr unknown
- 2012-07-13 ES ES12811865.0T patent/ES2671581T3/es active Active
- 2012-07-13 RU RU2014105169A patent/RU2612958C2/ru active
- 2012-07-13 CN CN201280034416.4A patent/CN103764655B/zh active Active
- 2012-07-13 AU AU2012281281A patent/AU2012281281B2/en active Active
- 2012-07-13 BR BR112014000774-8A patent/BR112014000774B1/pt active IP Right Grant
- 2012-07-13 JP JP2014520137A patent/JP6094975B2/ja active Active
- 2012-07-13 DK DK12811865.0T patent/DK2731949T3/en active
- 2012-07-13 MX MX2014000309A patent/MX369576B/es active IP Right Grant
-
2013
- 2013-06-07 NO NO13729240A patent/NO2861601T3/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2671581T3 (es) | 2018-06-07 |
| CA2841252C (en) | 2019-02-26 |
| EP2731949A2 (en) | 2014-05-21 |
| CN103764655A (zh) | 2014-04-30 |
| BR112014000774A8 (pt) | 2017-10-10 |
| CN103764655B (zh) | 2017-04-12 |
| MX369576B (es) | 2019-11-13 |
| KR101938368B1 (ko) | 2019-01-14 |
| TR201808033T4 (tr) | 2018-06-21 |
| RU2014105169A (ru) | 2015-08-20 |
| RU2612958C2 (ru) | 2017-03-14 |
| KR20140050048A (ko) | 2014-04-28 |
| AU2012281281A1 (en) | 2014-03-06 |
| EP2731949B1 (en) | 2018-04-04 |
| CA2841252A1 (en) | 2013-01-17 |
| AU2012281281B2 (en) | 2017-06-01 |
| BR112014000774B1 (pt) | 2022-03-29 |
| US10155763B2 (en) | 2018-12-18 |
| DK2731949T3 (en) | 2018-06-14 |
| WO2013009140A3 (en) | 2013-04-11 |
| NO2861601T3 (pt) | 2018-07-07 |
| JP6094975B2 (ja) | 2017-03-15 |
| PL2731949T3 (pl) | 2018-10-31 |
| JP2014520846A (ja) | 2014-08-25 |
| MX2014000309A (es) | 2014-02-27 |
| EP2731949A4 (en) | 2014-12-17 |
| US20130018052A1 (en) | 2013-01-17 |
| PT2731949T (pt) | 2018-06-15 |
| WO2013009140A2 (en) | 2013-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014000774A2 (pt) | compostos imidazóis substituídos por 2-piridilam como inibidores de alk5 e/ou alk4, seus usos e composições | |
| BR112013005523A2 (pt) | composto como inibidores de quinase c-met e seus usos | |
| CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
| CO7061086A2 (es) | Combinaciones de compuestos activos | |
| CO6900140A2 (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| CO6900141A2 (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| CL2014002903A1 (es) | Composición geopolimérica de aluminosilicato; método de preparacion y sus usos. | |
| BR112012029405A2 (pt) | compostos macrocíclicos como inibidores de trk quinase | |
| CO6811868A2 (es) | Combinaciones de principios activos | |
| CO6831983A2 (es) | Compuestos heterocíclicos como inhibidores de cinasas | |
| CO6960551A2 (es) | Derivados nucleósidos con sustitución 2,4-difluoro -2-metilo como inhibidores de la replicación del arn del vch | |
| BR112015032539A2 (pt) | compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase | |
| CR20130192A (es) | Derivados de bencimidazol como inhibidores de cinasa p13 | |
| DK2885010T3 (da) | Fremgangsmåder til behandling med tauopati | |
| BR112013022813A2 (pt) | diaminocarbonitrila pirimidinas e diaminocarboxamida substituída, composições das mesmas e métodos de tratamento com as mesmas | |
| BR112013016030A2 (pt) | compostos e seu uso como inibidores de bace | |
| BR112013007907A2 (pt) | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase | |
| FR2997014B1 (fr) | Composition sterile dermo-injectable | |
| CO6960555A2 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| CO6880065A2 (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| CO6862145A2 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| CO6900144A2 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| CL2014003059A1 (es) | Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose. | |
| EA201491303A1 (ru) | Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: TIUMBIO CO., LTD (KR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04 Ipc: C07D 487/04 (2006.01), A61K 31/4188 (2006.01), A61 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/07/2012, OBSERVADAS AS CONDICOES LEGAIS. |